Abstract:ObjectiveTo observe the clinical efficacy of Gongliuxiao combined with Methyltestosterone and Mifepristone in treatment of perimenopausal uterine fibroid.MethodsNinety-four patients with perimenopausal uterine fibroid admitted into the People′s Hospital of Nanchang County from April 2013 to April 2015 were selected,and they were divided into two groups according to the random number table method,47 cases in each group.Control group was given the treatment of Methyltestosterone and Mifepristone,and observation group was given the Gongliuxiao on this basis of the treatment of the control group.The clinical efficacy and adverse reactions of the two groups were compared;the hormone levels such as progesterone (P),follicle-stimulating hormone (FSH),luteinizing hormone (LH),estradiol(E2),and the changes of uterus volume and myoma volume of the two groups before and after treatment were observed.ResultsThe total effective rate of the observation group was 91.49%,significantly higher than 74.47%of the control group,the difference was statistically significant(P<0.05);before treatment,there was no significant difference in the progesterone levels,uterus volume and myoma volume between the two groups(P>0.05);after treatment,the improvement situation of hormone levels of the observation group was significantly better than the control group,and the reduction degree of uterus volume and myoma volume was significantly larger than that of the control group(P<0.05);there was no statistically significant difference in the adverse reactions between the two groups (P>0.05).ConclusionGongliuxiao combined with Methyltestosterone and Mifepristone has definite clinical efficacy,it can effectively promote the shrinking of uterine fibroid,relieve clinical symptoms and has value of clinical application.
饶美红. 宫瘤消联合甲睾酮、米非司酮治疗围绝经期子宫肌瘤的效果观察[J]. 中国当代医药, 2016, 23(35): 71-74.
RAO Mei-hong. Effect observation of Gongliuxiao combined with Methyltestosterone and Mifepristone in the treatment of perimenopausal uterine fibroid. 中国当代医药, 2016, 23(35): 71-74.